What is ImmunoScape?
ImmunoScape operates at the intersection of biotechnology and advanced data science, providing a sophisticated technology platform for the characterization of the human immune response. Its core offering, the Deep Immunomics platform, integrates mass cytometry, single-cell sequencing, and proprietary computational tools to deliver high-resolution, reproducible immune profiling data. This capability is essential for pharmaceutical and clinical research organizations seeking to understand complex immune dynamics in disease progression and therapeutic response.
By transforming raw biological data into actionable insights, ImmunoScape occupies a vital niche in the life sciences sector. The company's ability to visualize and analyze immune cell behavior at scale provides a competitive advantage in drug discovery and personalized medicine, where precision and data integrity are paramount. As the demand for granular immune data grows, ImmunoScape's platform serves as a foundational tool for researchers aiming to decode the complexities of the human immune system.
How much funding has ImmunoScape raised?
ImmunoScape has raised a total of $39M across 3 funding rounds:
Unspecified
$11M
Unspecified
$14M
Other Financing Round
$14M
Unspecified (2020): $11M with participation from Utec, Anzu Partners, and NPR Holdings
Unspecified (2021): $14M led by EDBI, University of Tokyo Edge Capital Partners, and Anzu Partners LLC
Other Financing Round (2022): $14M supported by EDBI and Anzu Partners
Key Investors in ImmunoScape
EDBI
EDBI is a global investor based in Singapore, focusing on high-growth technology sectors since 1991. The firm aims to create value and empower businesses to build sustainable legacies through strategic investments in biotechnology and other innovative fields.
Anzu Partners
Anzu Partners is an investment firm focused on breakthrough technologies in clean tech, industrial, and life sciences sectors. They provide expertise in business development and market positioning to support founders in bringing innovative solutions to market.
UTEC
UTEC is a venture capital firm approved by the University of Tokyo, focusing on investing in startups that leverage exceptional intellectual property. The firm collaborates with research institutions to source impactful technologies and foster innovation.
What's next for ImmunoScape?
With the successful closure of this major strategic investment, ImmunoScape is well-positioned to expand its operational footprint and enhance its bioinformatics suite. The company's roadmap likely involves scaling its data analysis capabilities to support larger clinical trials and broadening its partnerships within the global biopharmaceutical industry. By focusing on the integration of its proprietary tools into standard research workflows, ImmunoScape aims to solidify its market position as a leader in immunomics.
Future growth will likely be driven by the continued refinement of its visualization tools and the expansion of its intellectual property portfolio. As the company matures, the focus will shift toward commercializing its insights to support the development of next-generation immunotherapies, ultimately aiming to improve patient outcomes through a deeper understanding of immune-mediated diseases.
